(Q43045537)

12 November 2017

title

Risperidone versus olanzapine for the treatment of delirium (English)

1 reference

12 November 2017

1 reference

Sung-Wan Kim

1

1 reference

12 November 2017

Joon-An Yoo

2

1 reference

12 November 2017

Sam-Yeon Lee

3

1 reference

12 November 2017

Seon-Young Kim

4

1 reference

12 November 2017

Kyung-Yeol Bae

5

1 reference

12 November 2017

Su-Jin Yang

6

1 reference

12 November 2017

Jae-Min Kim

7

1 reference

12 November 2017

Il-Seon Shin

8

1 reference

12 November 2017

Jin-Sang Yoon

9

1 reference

12 November 2017

language of work or name

1 reference

1 June 2010

1 reference

12 November 2017

published in

Human Psychopharmacology

1 reference

12 November 2017

volume

25

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

298-302

1 reference

A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients

12 November 2017

cites work

1 reference

A double-blind trial of risperidone and haloperidol for the treatment of delirium

21 January 2018

1 reference

Agitation and delirium at the end of life: "We couldn't manage him".

21 January 2018

1 reference

7 January 2021

An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients

1 reference

7 January 2021

Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit

1 reference

7 January 2021

Delirium in elderly adults: diagnosis, prevention and treatment

1 reference

7 January 2021

Treatment for delirium with risperidone: results of a prospective open trial with 10 patients

1 reference

7 January 2021

Delirium in older persons

1 reference

7 January 2021

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

1 reference

7 January 2021

The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients

1 reference

7 January 2021

Efficacy of risperidone in treating the hyperactive symptoms of delirium

1 reference

7 January 2021

Delirium predicts 12-month mortality

1 reference

7 January 2021

Does delirium increase hospital stay?

1 reference

7 January 2021

Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients

1 reference

7 January 2021

Atypical antipsychotics for the treatment of delirious elders.

1 reference

7 January 2021

A pilot trial of quetiapine for the treatment of patients with delirium

1 reference

7 January 2021

Delirium: where do we stand?

1 reference

7 January 2021

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

1 reference

7 January 2021

The role of atypical antipsychotics in the treatment of delirium

1 reference

7 January 2021

Antipsychotics in the treatment of delirium: a systematic review

1 reference

7 January 2021

Olanzapine vs haloperidol: treating delirium in a critical care setting

1 reference

7 January 2021

Relationship between plasma concentration levels of risperidone and clinical effects in the treatment of delirium

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1117

1 reference

12 November 2017

1 reference